Inspra (Eplerenone)

Eplerenone works by selectively blocking the mineralocorticoid (aldosterone) receptor in the distal nephron. This inhibition reduces sodium reabsorption and potassium excretion, leading to decreased fluid volume, lower blood pressure, and less aldosterone‑driven cardiac fibrosis, which together support better heart function.

The appropriate dose of Inspra is individualized by the prescribing clinician based on the patient’s blood pressure, kidney function, serum potassium levels, and overall clinical condition. Dosage adjustments are made according to therapeutic response and laboratory monitoring, following local prescribing guidelines.

Inspra is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should only be used if the potential maternal benefit justifies any possible fetal risk, and breastfeeding decisions should be made after consulting a healthcare professional.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Inspra (eplerenone) and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer endocrine side effects such as gynecomastia. However, both share similar risks of hyperkalemia and require monitoring of potassium and renal function.

Inspra tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Inspra is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole with a glass of water and follow any specific timing instructions provided by their healthcare professional.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and significant renal impairment that may worsen kidney function. Prompt monitoring of serum potassium and renal parameters is essential to mitigate these risks.

Inspra should be avoided in patients with known hypersensitivity to eplerenone, those with severe hyperkalemia (serum potassium >5.0 mmol/L), and individuals with significant renal dysfunction where potassium accumulation is likely. Clinicians must also assess contraindications related to concomitant potassium‑raising therapies.